Docket #: S24-184
Antibody-Cytokine Fusions for Targeted Activation of Macrophages in Local Tumor Environment
Researchers from Stanford developed antibody-cytokine fusions and methods to provide targeted recognition of tumors, controlled cytokine release, and localized immune activation.
Cytokine therapy has the potential to stimulate potent antitumor immune responses; however, systemic cytokine exposure can cause significant toxicity and limit the therapeutic window. Furthermore, insufficient localization of cytokine activity to the tumor microenvironment may limit therapeutic efficacy
To address these issues, the inventors link a tumor-specific antibody to an immunologically active cytokine with a cleavable linker activated by a protease highly enriched in tumor tissue, with the goal of concentrating immune stimulation at tumor sites while limiting systemic exposure. In vitro and in vivo experiments have been conducted to assess cleavage efficiency, macrophage recruitment and activation, tumor targeting, therapeutic efficacy, and systemic toxicity. This antibody-cytokine conjugate establishes a new therapeutic strategy to treat tumors with high efficacy and low toxicity in a controlled and targeted manner.
Stage of Development
Methods have been demonstrated in vitro and in vivo
Applications
- Cancer immunotherapy
Advantages
- Enhanced efficacy
- Reduced systemic toxicity
- Targeted delivery and activation
Related Links
Similar Technologies
-
Enhanced vaccine efficacy using mRNA-LNP adjuvants S25-089Enhanced vaccine efficacy using mRNA-LNP adjuvants
-
Antibody-Targeted Molecular Glue Degraders for Selective Cancer Therapy S25-550Antibody-Targeted Molecular Glue Degraders for Selective Cancer Therapy
-
STASH system: Enriching genetically modified cells with a single selectable surface marker S20-432STASH system: Enriching genetically modified cells with a single selectable surface marker